TY - JOUR T1 - IMPROVE-DD: Integrating Multiple Phenotype Resources Optimises Variant Evaluation in genetically determined Developmental Disorders JF - medRxiv DO - 10.1101/2022.05.20.22275135 SP - 2022.05.20.22275135 AU - Stuart Aitken AU - Helen V Firth AU - Caroline F Wright AU - Matthew E Hurles AU - David R FitzPatrick AU - Colin A. Semple Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/21/2022.05.20.22275135.abstract N2 - Summary Diagnosing rare developmental disorders using genome-wide sequencing data commonly necessitates review of multiple plausible candidate variants, often using ontologies of categorical clinical terms. We show that Integrating Multiple Phenotype Resources Optimises Variant Evaluation in Developmental Disorders (IMPROVE-DD) by incorporating additional classes of data commonly available to clinicians and recorded in health records. In doing so, we quantify the distinct contributions of gender, growth, and development in addition to Human Phenotype Ontology (HPO) terms, and demonstrate added value from these readily-available information sources. We use likelihood ratios for nominal and quantitative data and propose a novel classifier for HPO terms in this framework. This Bayesian framework results in more robust diagnoses. Using data systematically collected in the DDD study, we considered 77 genes with pathogenic/likely pathogenic variants in >10 probands. All genes showed at least a satisfactory prediction by ROC when testing on training data (AUC≥0.6), and HPO terms were the best individual predictor for the majority of genes, though a minority (13/77) of genes were better predicted by other phenotypic data types. Overall, classifiers based upon multiple integrated phenotypic data sources performed better than those based upon any individual source, and importantly, integrated models produced notably fewer false positives. Finally, we show that IMPROVE-DD models with good predictive performance on cross-validation can be constructed from relatively few cases. This suggests new strategies for candidate gene prioritisation, and highlights the value of systematic clinical data collection to support diagnostic programmes.Competing Interest StatementM.E.H. is a co-founder, consultant, and non-executive director of Congenica Ltd. The remaining authors declare no competing interests.Funding StatementThe DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. The views expressed in this publication are those of the author(s) and not necessarily those of Wellcome or the Department of Health. The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. This study makes use of DECIPHER (https://www.deciphergenomics.org/), which is funded by the Wellcome. HVF is supported by the Wellcome Trust [award 200990/Z/16/Z] Designing, developing and delivering integrated foundations for genomic medicine. The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. DRF is funded as part of the MRC Human Genetics Unit grant to the University of Edinburgh. CAS and SA are supported by MRC Core funding to the MRC Human Genetics Unit (MRC grant MC_UU_00007/16).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used only data available at https://www.deciphergenomics.org/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available at https://www.deciphergenomics.org/ https://www.deciphergenomics.org/ ER -